Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-3140 + immune checkpoint inhibitor
- Development stage
- Preclinical
- Lead developer
- PURMX Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-3140 + immune checkpoint inhibitor is a combination therapy being developed by PURMX Therapeutics. It consists of a miR-3140-based miRNA therapeutic (likely a mimic of the endogenous microRNA) combined with an immune checkpoint inhibitor (ICI) to enhance antitumor immune responses. miR-3140 is a microRNA that acts as a tumor suppressor by regulating multiple oncogenic pathways, including the targeting of MAP3K3 and BRD4. The combination strategy aims to leverage the direct tumor-suppressive effects of miR-3140 alongside the immune-reinvigorating properties of checkpoint blockade (such as PD-1/PD-L1 or CTLA-4 inhibitors) to treat solid tumors. The program is currently in preclinical development.
- Other names
- miR-3140 + ICI
02
Targets
Bromodomain-containing protein 4 (BRD4) mRNA 3' untranslated regionMAP3K3Checkpoint (Immune checkpoints)
Beyond the preview
Go deeper on miR-3140 + immune checkpoint inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-3140 + immune checkpoint inhibitor.